QPS Taiwan Awarded GLP-Laboratory Certification by DOH, Taiwan
Newark, DE
QPS, a leading GLP/GCP‑compliant contract research organization providing testing services to support preclinical and clinical research and development, announced today that QPS Taiwan, its Asian operation, has been awarded a Good Laboratory Practice (GLP)‑laboratory certification by the Department of Health (DOH), Executive Yuan, R.O.C. (Taiwan). QPS received this certification due to their exceptional track record and scientific infrastructure, including global Standard Operating Procedures (SOPs), understanding of the regulatory agency of requirement, and planning for the implementation of systems and processes within the Taiwan facility.
“QPS Taiwan has been awarded the first and only GLP-laboratory certification by DOH, Taiwan for bioanalytical services supporting preclinical and clinical research,” stated QPS Taiwan President and CEO, Vincent Yen, M.B.A. “QPS Taiwan shares the same criteria, global SOPs, laboratory procedures, equipment (API 4000 triple quadrupole mass spectrometers, Shimadzu VP-series LCs, Tomtec Quadra), laboratory operations (Rees Monitors, Watson LIMS systems), and systems and processes as QPS U.S.A. We are excited about this certification..."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
